EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Perioperative management of anticoagulant therapy

Johanna Wagner iD, Johan F Lock, Carolin Kastner, Ingo Klein, Katica Krajinovic, Stefan Löb, Christoph-Thomas Germer, Armin Wiegering

Innovative Surgical Sciences · 18.12.2019 · 4 (4) · 144-151

DOI: 10.1515/iss-2019-0004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Innovative Surgical Sciences, erschienen am 18.12.2019. Verfasst von Johanna Wagner und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General, Visceral, Transplantation, Vascular and Pediatric Surgery, Medical Center Julius-Maximilians, University of Wuerzburg, Oberdue…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

About 10% of patients taking a chronic, oral anticoagulant therapy require an invasive procedure that can be associated with an increased risk for peri-interventional or perioperative bleeding. Depending on the risk for thromboembolism and the risk for bleeding, the physician has to decide whether the anticoagulant therapy should be interrupted or continued. Patient characteristics such as age, renal function and drug interactions must be considered. The perioperative handling of the oral anticoagulant therapy differs according to the periprocedural bleeding risk. Patients requiring a procedure with a minor risk for bleeding do not need to pause their anticoagulant therapy. For procedures with an increased risk for perioperative bleeding, the anticoagulant therapy should be adequately paused. For patients on a coumarin derivative with a high risk for a thromboembolic event, a perioperative bridging therapy with a low molecular weight heparin is recommended. Due to an increased risk for perioperative bleeding in patients on a bridging therapy, it is not recommended in patients with a low risk for thromboembolism. For patients taking a non-vitamin K oral anticoagulant, a bridging therapy is not recommended due to the fast onset and offset of the medication.

Schlagwörter

Stichwörter der Autor:innen

NOACanticoagulationbridgingdalteparinenoxaparinperioperative periodwarfarin

Autor:innen und Institutionen

  • Department of General, Visceral, Transplantation, Vascular and Pediatric Surgery, Medical Center Julius-Maximilians, University of Wuerzburg, Oberduerrbacherstr. 6, 97080 Wuerzburg, Germany.
  • Department of General, Visceral, Transplantation, Vascular and Pediatric Surgery, University Hospital Würzburg, Wüerzburg, Germany.
  • Comprehensive Cancer Center Mainfranken, Würzburg, Germany.
  • Department of Biochemistry and Molecular Biology, University of Würzburg, Würzburg, Germany.

ORCID-Profile: Johanna Wagner

Zitieren

APA

Wagner, J., Lock, J. F., Kastner, C., Klein, I., Krajinovic, K., Löb, S., Germer, C. T., & Wiegering, A. (2019). Perioperative management of anticoagulant therapy. Innovative Surgical Sciences, 4(4), 144-151. https://doi.org/10.1515/iss-2019-0004

Vancouver

Wagner J, Lock JF, Kastner C, Klein I, Krajinovic K, Löb S, et al. Perioperative management of anticoagulant therapy. Innovative Surgical Sciences. 2019;4(4):144-151. doi:10.1515/iss-2019-0004

BibTeX
@article{Wagner2019,
  author = {Wagner, Johanna and Lock, Johan F and Kastner, Carolin and Klein, Ingo and Krajinovic, Katica and Löb, Stefan and Germer, Christoph-Thomas and Wiegering, Armin},
  title = {Perioperative management of anticoagulant therapy},
  journal = {Innovative Surgical Sciences},
  year = {2019},
  volume = {4},
  number = {4},
  pages = {144--151},
  doi = {10.1515/iss-2019-0004}
}
Kostenlos starten →